Literature DB >> 18624032

Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines.

Martin Cadogan1, Angus G Dalgleish.   

Abstract

More than a decade ago, the pathogenesis of AIDS was reviewed in this journal, using the subtitle 'classical and alternative views', when evidence was accumulating that HIV could not cause AIDS simply through direct cytopathic mechanisms alone. Generalised immune activation after infection with HIV is now understood to be associated with and predictive of disease progression and probably represents the single most important difference between rapid progression and slow or non-progression. However, the fundamental source of this phenomenon remains undetermined. Do pathogenic events after acute infection promote an environment susceptible to increased hyperactivity or does inherent reactivity towards HIV in susceptible individuals ultimately influence these processes? New strategies aimed at eliminating HIV-induced immune activation are required, as is investigation into the clinical and immunological influence of antibodies that target HIV epitopes associated with disease and that are not necessarily neutralising. Therapeutic vaccines to prevent disease may be more practical and effective than classic prophylactic vaccination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18624032      PMCID: PMC4953827          DOI: 10.7861/clinmedicine.8-3-267

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  3 in total

Review 1.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection.

Authors:  Galit Alter; Daniel Kavanagh; Suzannah Rihn; Rutger Luteijn; David Brooks; Michael Oldstone; Jan van Lunzen; Marcus Altfeld
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

3.  The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study.

Authors:  Kristin Brekke; Maja Sommerfelt; Mats Ökvist; Anne Margarita Dyrhol-Riise; Dag Kvale
Journal:  BMC Infect Dis       Date:  2017-03-24       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.